Myocardial Bridging
Conditions
Interventions
Control Group:Placebo
Sponsors
Zhongshan Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18–75 years (inclusive), regardless of gender. 2. Patients with angina or anginal equivalent symptoms (pressure-like discomfort in the chest, neck, jaw, shoulder, or arm; precipitated by physical exertion; relieved within 5 minutes by rest or nitroglycerin use) occurring at a frequency of =2 times per week. 3.Diagnosis: Confirmed myocardial bridge in the left anterior descending (LAD) artery via coronary angiography or coronary CTA, including: Patients with isolated myocardial bridge in the LAD artery; Patients with myocardial bridge in the LAD artery and <50% stenosis in all epicardial coronary arteries. 4.Consent: Signed informed consent form.
Exclusion criteria
Exclusion criteria: 1.Coronary Stenosis: =50% stenosis in any epicardial coronary artery confirmed by coronary angiography or coronary CTA. 2.Recent ACS: Diagnosis of acute coronary syndrome (ACS) within the past 12 months. 3.Prior Revascularization: Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within the past 12 months. 4.Non-Cardiac Chest Pain: Comorbidities that may cause chest pain (e.g., severe pulmonary hypertension, severe aortic stenosis, or obstructive hypertrophic cardiomyopathy). 5.Severe Anemia: Hemoglobin 180 mmHg or diastolic blood pressure >110 mmHg. 8.Uncontrolled Arrhythmias: Hemodynamically unstable arrhythmias (e.g., rapid atrial fibrillation, supraventricular tachycardia, high-grade atrioventricular block). 9.Recent Medication Use: Use of ß-blockers, calcium channel blockers, Kuanxiong Aerosol, or herbal preparations (e.g., Tongxinluo, Shexiang Baoxin Pills, Compound Danshen Dripping Pills) within 2 weeks prior to enrollment. *Note: A 2-week washout period is required; eligibility may be reassessed thereafter. 10.Allergy History: Hypersensitivity to alcohol or components of Kuanxiong Aerosol (including documented allergy or prior allergic reactions). 11.Severe Systemic Diseases: Active malignancy or other severe systemic disorders. 12.Pregnancy: Pregnant women or women planning pregnancy. 13.Concurrent Trials: Participation in another clinical trial or prior randomization in this study within 30 days before screening. 14.Investigator Discretion: Patients deemed ineligible by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seattle Angina Questionnaire (SAQ); | — |
Secondary
| Measure | Time frame |
|---|---|
| Anxiety/Depression Scales: Generalized Anxiety Disorder-7 (GAD-7) Patient Health Questionnaire-9 (PHQ-9);Treadmill Exercise Testing;Frequency of Angina Episodes;Seattle Angina Questionnaire (SAQ);12-Item Short Form Survey (SF-12 );Cardiopulmonary Exercise Testing; | — |
Countries
China
Contacts
Public ContactJunboGe
Zhongshan Hospital
Outcome results
None listed